Based on the expression level of ANTXR1 in GC, clinicians could select currently available standard medicine or potential monoclonal antibodies that target ANTXR1 proteins to maximize the benefits to patients, if confirmed in prospective studies, which would improve the clinical outcomes of GC patients. This evidence concerns the gene ANTXR1 and gastric cancer.